scabies
SCABIES
Scabies is a contagious disease caused by the mite Sarcoptes scabiei var hominis.
The affected individual usually complains of having a highly pruritic rash that occurs at night.
It occurs more often in children <15 years of age, sexually active young adults, the immunocompromised and in persons living in crowded living conditions (eg nursing homes, military barracks).
Transmission is typically by direct skin contact with an infected person and in adults, sexual transmission is common.

Introduction

  • Diagnosis is made based on clinical presentation and can be confirmed by microscopic identification of mites, eggs or mite feces
  • Scabies should be suspected in a patient who presents with a highly pruritic rash with nocturnal predominance
    • Scabies is highly suggested if there is also a history of contact with an infected person or if there is a history of contact with family member or sexual partner who has pruritic lesions with nocturnal predominance
  • Scabies is caused by the mite: Sarcoptes scabiei var hominis
  • Occurs more often in children <15 years, sexually active young adults, the immunocompromised and in persons living in crowded living conditions (eg nursing homes, military barracks)
  • Transmission is typically by direct skin contact with an infected person and in adults, sexual transmission is common
    • Though there is limited documentation, transmission by fomites may be possible (especially in cases of crusted scabies where a large amount of parasites are involved)
    • The mites can live for up to 30 days on a host and remain alive for 3 days on furniture, bedding, etc

Signs and Symptoms

  • Primary symptom is generalized pruritus, which is usually worse at night
    • Pruritus is caused by a delayed (type IV) hypersensitivity reaction to the mite and its products (saliva, eggs and feces) once the host becomes sensitized
    • Hypersensitivity occurs 3-6 weeks after infestation but occurs in 1-3 days with re-infestation because the host has been previously sensitized
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.